5Cai Z, Dean R, Wu L, et al. Role of angiotensin receptor subtypes in mescntcric vascular proliferation and Hypertrophy [ J ]. hypertension, 1999,34 ( 3 ) :408 -414.
6Nickenig G, Harrison DG The AT1-type angiotensin receptor in exidative stress and atherogenesis[ J]. Circulation, 2002;105:393 -396.
7Wu L, Iwai M,Nakagami H,et al. Roles of angiotensinll type2 receptor stimulation associated with selective angiotensinⅡ type receptor blockade with valsartan in the improvement of inflammation-induced vascular injury [ J ]. Circulation, 2001,104:2716-2721.
8pfeffer MA,MeMurray JJV, Velazquez EJ,et al. Valsartan,captopril or both in myocardial infarction complicated by heart failure, leftventricular dysfunction, orboth [ J ]. N Eegl J Med ,2003 ,349 :1893-1906.
9Com JN,Tognoni G. Arandomized trial of the angiotensin receptorblocker valsartan in chronic heart failure[J]. J Med,2001,345 :1667-1675.
二级参考文献6
1[1]THRMANN PA. Angiotensin II antagonism and the heart: valsartan in left ven tricular hypertrophy [J]. J Cardiovasc Pharmacol ,1999, 33 Suppl 1:S33-S36.
2[2]PLUM J, BNTEN B, N**METH R, et al. Effects of the angiotensin II ant agonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients wit h chronic renal failure and hypertension [J]. J Am Soc Nephrol, 1998, 9(12): 2 223-2234.
3[3]BREMNER AD, BAUR M, ODDOU-STOCK P, et al. Valsartan: long term effica cy and tolerability compared to lisinopril in elderly patients with essential hypertens ion [J]. Clin Exp Hypertens, 1997, 19(8): 1263-1285.
4[4]MARKHAM A, GOA KL. Valsartan a review of its pharmacology and therapeutic use in essential hypertension [J]. Drugs ,1997 ,54(2): 299-311.
5[5]BLACK HR, GRAFF A, SHUTE D, et al. Valsartan, a new angiotensin II ant agonis t for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril [J]. J Hu m Hypertens, 1997,11(8): 483-489.
